Immunohistochemical expression of ubiquitin and telomerase in cervical cancer.
Ubiquitin and telomerase immunohistochemical expression patterns in cervical cancer were compared with normal cervical tissue samples. Eighty-one cervical cancer cases and 22 normal exo-endocervical tissue were examined with polyclonal antibody for ubiquitin and 44G12 clone for telomerase using tissue microarrays. The results were interpreted using a semiquantitative scale The average age of patients was 50.67 years. The most frequent histological types were moderately differentiated epidermoid carcinoma (43.5%), according to the degree of differentiation, and endocervical adenocarcinoma (42.1%). Immunohistochemical findings were as follows: 98.7% of cervical cancers showed immunoexpression for ubiquitin and 52.6% for telomerase. Statistically significant differences were found in tumor immunoreactivity when compared with control tissue (p < 0.0007) for both biomarkers. There was no significant difference in biomarker expression at different histological types of tumors, although telomerase was less expressed in endocervical adenocarcinoma. Our findings confirm that abnormal immunoexpression pattern of ubiquitin and telomerase is common in HPV-positive cervical cancer, indicating the existence of an intense degradation of proteins, subsequent cellular immortalization and maintenance of the malignant phenotype.
Morelva
Toro de Méndez
Tde M
Exfoliative Cytology, Faculty of Pharmaceutics and Analytical Biosciences, University of Los Andes, Mérida, Venezuela. tmorelva@ula.ve
Antonio
Llombart Bosch
LB
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D002584:Cervix Uteri / Q000737:chemistry; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D027383:Papillomaviridae / Q000302:isolation & purification; D019098:Telomerase / Q000032:analysis*; D046888:Tissue Array Analysis; D025801:Ubiquitin / Q000032:analysis*; D002583:Uterine Cervical Neoplasms / Q000737:chemistry* / Q000821:virology
D014408:Biomarkers, Tumor; D025801:Ubiquitin; D019098:Telomerase
Invest Clin. 2005 Sep;46(3):255-63
16152781
Diagn Cytopathol. 2006 Nov;34(11):739-48
17041957
J Immunol. 2001 Apr 15;166(8):4826-30
11290757
Oncogene. 2002 Jan 21;21(4):664-73
11850794
Semin Cancer Biol. 2003 Feb;13(1):59-67
12507557
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2563-7
7708685
Oncogene. 2003 Aug 11;22(33):5201-7
12910257
J Biol Chem. 1997 Nov 28;272(48):30135-40
9374493
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8211-6
12821782
Cell. 2000 Jan 7;100(1):57-70
10647931
Pharmacol Ther. 1998 Jun;78(3):129-39
9690814
Br J Cancer. 2007 Apr 10;96(7):1020-4
17353922
EMBO J. 2005 Oct 5;24(19):3353-9
16148945
Histochem Cell Biol. 2004 May;121(5):391-7
15138842
Am J Pathol. 1997 Jul;151(1):25-31
9212727
FASEB J. 1997 Nov;11(13):1067-75
9367342
J Virol. 2001 Aug;75(15):7198-201
11435602
Oncol Rep. 2002 Jan-Feb;9(1):43-9
11748453
Eur J Cancer. 1997 Apr;33(5):787-91
9282118
N Engl J Med. 1996 Dec 19;335(25):1897-905
8948566
J Virol. 2000 Jul;74(14):6408-17
10864652
Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1218-23
11158620
Gynecol Oncol. 1998 Feb;68(2):145-9
9514809
J Mol Med (Berl). 1997 Jan;75(1):5-17
9020379
Cancer Res. 1996 Oct 15;56(20):4620-4
8840974
Chin Med J (Engl). 2004 Feb;117(2):202-6
14975203
J Natl Cancer Inst. 2000 May 3;92(9):690-8
10793105
Hum Pathol. 2004 Apr;35(4):396-402
15116318
J Virol. 2001 May;75(9):4467-72
11287602
N Engl J Med. 2003 Feb 6;348(6):518-27
12571259
Am J Clin Pathol. 1998 Feb;109(2):153-62
9583886
Zentralbl Gynakol. 2001 Apr;123(4):186-91
11370525
J Virol. 2001 Aug;75(16):7583-91
11462030
J Clin Pathol. 2005 Sep;58(9):911-4
16126869
Vaccine. 2006 Aug 31;24 Suppl 3:S3/42-51
16950017
Yonsei Med J. 2005 Oct 31;46(5):597-613
16259056
J Virol. 2001 Jun;75(12):5559-66
11356963
J Clin Pathol. 2003 Jan;56(1):31-5
12499429
Am J Pathol. 2003 Sep;163(3):859-67
12937127
Cancer. 1998 Apr 1;82(7):1319-27
9529024
Cancer Res. 1998 Apr 1;58(7):1558-61
9537264